BioPharma Resources

Drug Trial Radar · NCT04864444

Mass Drug Administration of Dihydroartemisinin-piperaquine + Single Low-dose Primaquine to Accelerate Toward Elimination Activities

Mass Drug Administration With Dihydroartemisinin-piperaquine and Primaquine to Reduce Malaria in a Moderate-low Transmission Setting in Senegal: A Cluster Randomized Controlled Trial

Last checked: Nov 19, 2026Latest source record: Jun 24, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 10,715 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

10,715

Actual

Start

Jun 19, 2021

Primary completion

Dec 31, 2022

Study completion Jun 30, 2023

Sponsor

Lead sponsor
University of California, San FranciscoAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
L'université de Thiès; Programme National de Lutte contre le Paludisme, Niger; Population Services International; Centers for Disease Control and Prevention; US President's Malaria Initiative
First posted
Apr 28, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 3 months
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This community-based cluster randomized controlled trial aims to evaluate the effectiveness of time-limited, community-wide mass drug administration (MDA) with dihydroartemisinin-piperaquine (DHA-PPQ) and single low-dose primaquine (SLD-PQ) on Plasmodium falciparum transmission compared to standard-of-care seasonal malaria chemoprevention (SMC). The study will be conducted in a moderate-to-low malaria transmission setting of Senegal with optimized malaria control measures (e.g., proactive community case management and piperonyl butoxide pyrethroid long-lasting insecticidal nets (PBO LLINS)).

Conditions

  • Malaria,Falciparum
  • Malaria

Interventions

  • Dihydroartemisinin-piperaquineDrug

    DHA-PPQ will be given over the course of three consecutive days using 160mg/20mg or 320mg/40mg of dihydroartemisinin/piperaquine tablets. DHA-PPQ will be administered via age-based dosing. All three doses will be directly observed and given orally with water and without food.

  • PrimaquineDrug

    Primaquine will be given once with the first dose of DHA-PPQ. Primaquine will be administered in an aqueous solution according to age-based dosing guidelines.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Difference in village-level confirmed incidence of malariaTime frame: one year post-MDA

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Tambacounda Health District

    Tambacounda, Senegal

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.